Stock Market Reviews

MYGN (Myriad Genetics, Inc.) News

Get the latest news, insights, and market updates on MYGN (Myriad Genetics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia
  Nov 11, 2025 - $MYGN
• Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
  SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET. The presentations will be a
  Nov 11, 2025 - $MYGN
• 3 Volatile Stocks We Steer Clear Of
  Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.
  Nov 10, 2025 - $MYGN
• The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings Call
  Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted negatively due to ongoing challenges in average revenue per test and operational headwinds. Management cited continued strong volume growth in the oncology segment, particularly for its MyRisk hereditary cancer test, as a positive. CEO Samraat Raha noted, “MyRisk continues to see positive demand in the market and supports our profitable growth journey,” while also acknowle
  Nov 10, 2025 - $MYGN
• Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
  100% of genes strongly recommended by national oncology guidelines are included in the MyRisk TestSALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk® Hereditary Cancer Test—the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical
  Nov 10, 2025 - $MYGN
• QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
  GERMANTOWN, Md. & VENLO, Netherlands, November 10, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston.
  Nov 10, 2025 - $MYGN
• Does Neogen's (NEOG) CFO Transition Signal a New Phase for Its Financial Strategy?
  Neogen Corporation recently announced that Bryan Riggsbee has been appointed as its new Chief Financial Officer and Senior Vice President, effective November 3, 2025, succeeding David Naemura who will remain through year-end for a smooth transition. Riggsbee brings more than 25 years of financial leadership experience from key roles at bioMérieux and Myriad Genetics, adding significant industry expertise to Neogen's executive team. We will look at how Riggsbee's extensive diagnostics finance...
  Nov 9, 2025 - $MYGN
• Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
  SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among the pro
  Nov 6, 2025 - $MYGN
• Myriad Genetics (MYGN): Net Profit Margin Stalls as Losses Deepen, Underscoring Market Skepticism
  Myriad Genetics (MYGN) remains in the red, with losses having grown at an average annual rate of 21.1% over the last five years and no improvement in net profit margin compared to the prior year. While the company is expected to continue posting losses for at least three more years, revenue is forecast to climb by 4.5% per year, which trails the US market's 10.5% growth rate. Despite these ongoing challenges, Myriad’s pricing sits well below sector averages, drawing attention from investors...
  Nov 5, 2025 - $MYGN
• MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds
  Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $823 million at the midpoint. Its non-GAAP profit of $0 per share was $0.01 above analysts’ consensus estimates.
  Nov 4, 2025 - $MYGN